Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy Schiffman

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Breast Cancer Research and Treatment|August 2, 2002
Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patientsKathy Schiffman, Kristine Rinn, Mary L Disis
Expert Review of Neurotherapeutics|October 9, 2009
Immunotherapy of glioblastoma multiformeKeith L Knutson, Lupe Salazar, Kathy Schiffman, et al.
Journal of Clinical Immunology|September 11, 2004
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patientsMary L Disis, Vivian Goodell, Kathy Schiffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityKeith L Knutson, Kathy Schiffman, Martin A Cheever, et al.
Clinical Breast Cancer|September 3, 2005
Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancerAdam Brufsky, Barry Lembersky, Kathy Schiffman, et al.
Cancer Research|February 8, 2005
Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinaseR Bruce Montgomery, Ekram Makary, Kathy Schiffman, et al.
Expert Opinion on Biological Therapy|January 5, 2002
Adoptive T-cell therapy for the treatment of solid tumoursKeith L Knutson, Bond Almand, David A Mankoff, et al.
Journal of Clinical Immunology|March 21, 2003
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvantDouglas G McNeel, Keith L Knutson, Kathy Schiffman, et al.
Blood|April 4, 2002
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancersMary L Disis, Kristine Rinn, Keith L Knutson, et al.
Clinical Immunology (Orlando, Fla.)|October 5, 2007
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancersLupe G Salazar, Andrew L Coveler, Ron E Swensen, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Breast Cancer Research and Treatment|August 2, 2002
Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patientsKathy Schiffman, Kristine Rinn, Mary L Disis
Expert Review of Neurotherapeutics|October 9, 2009
Immunotherapy of glioblastoma multiformeKeith L Knutson, Lupe Salazar, Kathy Schiffman, et al.
Journal of Clinical Immunology|September 11, 2004
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patientsMary L Disis, Vivian Goodell, Kathy Schiffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityKeith L Knutson, Kathy Schiffman, Martin A Cheever, et al.
Clinical Breast Cancer|September 3, 2005
Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancerAdam Brufsky, Barry Lembersky, Kathy Schiffman, et al.
Cancer Research|February 8, 2005
Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinaseR Bruce Montgomery, Ekram Makary, Kathy Schiffman, et al.
Expert Opinion on Biological Therapy|January 5, 2002
Adoptive T-cell therapy for the treatment of solid tumoursKeith L Knutson, Bond Almand, David A Mankoff, et al.
Journal of Clinical Immunology|March 21, 2003
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvantDouglas G McNeel, Keith L Knutson, Kathy Schiffman, et al.
Blood|April 4, 2002
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancersMary L Disis, Kristine Rinn, Keith L Knutson, et al.
Clinical Immunology (Orlando, Fla.)|October 5, 2007
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancersLupe G Salazar, Andrew L Coveler, Ron E Swensen, et al.
Pageof 2